Increased expression of MED10 is associated with poor outcome in liver, renal cancer and glioma (MED10 prognostics from https://www.proteinatlas.org/ENSG00000133398-MED10, Uhlén et al, 2015). This evidence concerns the gene MED10 and central nervous system cancer.